Search results
15 cze 2020 · The latest update to the Global Initiative for Asthma (GINA) guidelines includes significant changes to treatment recommendations, especially a recommendation against using a short-acting beta...
Key Points for Practice. • In patients 12 years and older with mild, persistent asthma, intermittent low-dose ICS and as-needed inhaled SABAs should be used as rescue therapy instead of daily...
GINA recommends treating patients with mild intermittent asthma with as-needed inhaled corticosteroids (ICS) with short-acting beta 2 agonists (SABAs) for children six to 11 years of age and as...
Pocket Guide for asthma management and prevention for adults and children older than 5 years (updated 2020). Summary for primary health care providers, to be used in conjunction with the main GINA report. Difficult-to-treat and severe asthma in adolescent and adult patients. Diagnosis and Management.
Treatment: One regimen used in two reviewed studies is budesonide inhalation suspension, 1 mg twice daily for 7 days at the first sign of respiratory tract infection-associated symptoms. Potential benefits: The main benefit during respiratory tract infections is a reduction in exacerbations requiring systemic corticosteroids.
The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group was coordinated and supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
For individuals with moderate to severe persistent asthma already taking low- or medium-dose ICS, the preferred treatment is a single inhaler with ICS-formoterol (referred to as single maintenance and reliever therapy, or “SMART”) used both daily and as needed.
